Article Text

Download PDFPDF
The science, economics, and effectiveness of combination therapy for hepatitis C
  1. B READ
  1. 33B Nevill Road, Stoke Newington
  2. London NW16 8SW, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Editor,—No one affected by hepatitis C virus (HCV) will question Professor Dusheiko's insistence on the importance of effective therapy standards for HCV and the funding to meet them (OpenUrlFREE Full Text). With research and clinical evidence pointing to a prevalence of HCV infection far in excess of human immunodeficiency virus (HIV),1 the issue has now become urgent. Patients and clinicians alike will await the forthcoming NICE appraisal in the hope it recommends in favour of allocating sufficient resources to cover treatment costs for those most in need and best able to benefit.

However, while a positive response will be welcome it will also uncover issues that have still to be fully addressed. These centre on who will/should be selected for treatment …

View Full Text